Loading...
•
Mar 31, 2020
Cue Biopharma Q1 2020 Earnings Report
Cue Biopharma reported first quarter 2020 results and provided updates on the CUE-101 Phase 1 dose escalation study and recent business highlights.
Key Takeaways
Cue Biopharma reported collaboration revenue of $0.9 million for the first quarter of 2020. Research and development expenses were $9.9 million, and general and administrative expenses were $3.9 million. The company's net loss for the quarter was $12.818 million, or $0.48 per share.
Collaboration revenue increased to $0.9 million from $0.4 million year-over-year.
Research and development expenses increased to $9.9 million due to clinical trial costs and manufacturing of CUE-101.
General and administrative expenses increased to $3.9 million due to stock-based compensation and legal/accounting fees.
Extended cash runway through an ATM equity offering sales agreement for aggregate proceeds of $34.3 million.
Revenue by Segment
Forward Guidance
The press release does not contain forward guidance. Therefore, this field is empty.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...